Clovis Oncology Inc Logo Image

Clovis Oncology Inc

Clovis Oncology Inc has reached its limit for report views.

Please check back to see if Clovis Oncology Inc has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.

Most Recent Annual Report

2016 Annual Report and Form 10K

Clovis Oncology Inc

Clovis Oncology Inc does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



Archived Annual Reports

About Clovis Oncology Inc

201-500 Employees
Based in Boulder, Colorado

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer; Rucaparib, an oral inhibitor of poly polymerase, which is in advanced clinical development for the treatment of ovarian cancer; and Lucitanib, an oral inhibitor of the tyrosine kinase that is in Phase II development for the treatment of breast and lung cancers.

Ticker:
CLVS
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol